Anabela Rodrigues

Anabela Rodrigues

Auto-generated profile, based on publicly available information

Anabela Rodrigues

Nephrology Department, Unidade Local de Saúde de Santo António; UMIB - Unidade Multidisciplinar de Investigação Biomédica, ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto; ITR - Laboratory for Integrative and Translational Research in Population Health, UMIB- Unit for Multidisciplinary Research in Biomedicine; Porto, Portugal

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PPPedro R. Pereira
Pedro R. Pereira
David CarragetaDavid Carrageta
David Carrageta
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
ARAnabela Rodrigues
Anabela Rodrigues
Marco AlvesMarco Alves
Marco Alves
MMMariana Monteiro
Mariana Monteiro

1 April 2005 in Kidney International
Verified
Journal Article
Closed access
SDSimon J. Davies
Simon J. Davies
EBEdwina A. Brown
Edwina A. Brown
NFNiels E. Frandsen
Niels E. Frandsen
ARAnabela S. Rodrigues
Anabela S. Rodrigues
ARAna Rodriguez-Carmona
Ana Rodriguez-Carmona
JFJose C. Divino Filho
Jose C. Divino Filho

Verified
Journal Article
Open access
PDF file
Patricia Crespo BragaPatricia Crespo Braga
Patricia Crespo Braga
Marco AlvesMarco Alves
Marco Alves
ARAnabela S. Rodrigues
Anabela S. Rodrigues
Pedro F. OliveiraPedro F. Oliveira
Pedro F. Oliveira
In healthy kidneys, interstitial fibroblasts are responsible for the maintenance of renal architecture. Progressive interstitial fibrosis is thought to be a common pathway for chronic kidney diseases (CKD). Diabetes is one of the boosters of CKD. There is no effective treatment to improve kidney function in CKD patients. The kidney is a highly demanding organ, rich in redox reactions occurring in mitochondria, making it particularly vulnerable to oxidative stress (OS). A dysregulation in OS leads to an impairment of the Electron transport chain (ETC). Gene deficiencies in the ETC are closely related to the development of kidney disease, providing evidence that mitochondria integrity is a key player in the early detection of CKD. The development of novel CKD therapies is needed since current methods of treatment are ineffective. Antioxidant targeted therapies and metabolic approaches revealed promising results to delay the progression of some markers associated with kidney disease. Herein, we discuss the role and possible origin of fibroblasts and the possible potentiators of CKD. We will focus on the important features of mitochondria in renal cell function and discuss their role in kidney disease progression. We also discuss the potential of antioxidants and pharmacologic agents to delay kidney disease progression.

6 February 2007 in American Journal of Nephrology
Verified
Journal Article
Closed access
ARAnabela S. Rodrigues
Anabela S. Rodrigues
MMMargarida Martins
Margarida Martins
JKJohanna C. Korevaar
Johanna C. Korevaar
SSSandra Silva
Sandra Silva
JOJosé C. Oliveira
José C. Oliveira
RKRaymond T. Krediet
Raymond T. Krediet
Background/Aim: The determinants of baseline fast solute transport are still unclear. We prospectively investigated the relationship of peritoneal solute transport with markers of inflammation, angiogenesis, and membrane status, with a focus on fast transporters. Methods: Seventy-one incident peritoneal dialysis patients were assessed with baseline and annual peritoneal equilibration tests, using a 3.86% glucose dialysis solution. Residual renal function and markers of inflammation, including systemic and intraperitoneal interleukin-6 (IL-6), effluent cancer antigen 125 (CA-125), and vascular endothelial growth factor (VEGF) appearance rates (ARs), were investigated. The time course of the dialysate-to-plasma ratio of creatinine (D/P creatinine ratio) and its relationship with the biomarkers were investigated by a mixed linear model. Results: Incident fast/fast average transporters had a similar age, diabetes prevalence, and serum and effluent IL-6 levels, but significantly higher levels of CA-125 and VEGF ARs than the slow/slow average group; the D/P creatinine ratio was not correlated with systemic IL-6, but was correlated with effluent CA-125 AR (r = 0.45, p < 0.0001) and VEGF AR (r = 0.52, p < 0.0001). The D/P creatinine ratio decreased with a U-shaped profile (p = 0.02). Intraperitoneal IL-6 was the significant and positive determinant of the time course of the D/P creatinine ratio (p < 0.0001). Effluent CA-125 decreased with time on peritoneal dialysis (p = 0.013). Conclusions: Baseline peritoneal fast transport was not associated with systemic inflammation, but was related to peritoneal locally produced substances able to mediate transitory hyperpermeability. The D/P creatinine ratio changed during the follow-up period with a U-shaped profile. This was associated with effluent IL-6 and partly with VEGF. CA-125 decreased throughout the follow-up period.

6 December 2005 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
ARAnabela S. Rodrigues
Anabela S. Rodrigues
MAManuela Almeida
Manuela Almeida
IFIsabel Fonseca
Isabel Fonseca
MMMargarida Martins
Margarida Martins
MCMaria J. Carvalho
Maria J. Carvalho
ACAntónio Cabrita
António Cabrita
Background. The determinants of peritoneal fast transport status at the beginning of peritoneal dialysis (PD) are still under debate. The relationship between fast transport status and inflammation or co-morbidity, and its impact on patient survival are not fully elucidated. Our objective was to investigate if fast transport status in incident patients is associated with markers of inflammation and atherosclerosis, and its relationship to patient survival. Methods. Seventy-three incident patients on PD performed a 3.86% peritoneal equilibrium test (PET) at 4.7±2.7 months after starting PD. Doppler carotid wall intima-media thickness (IMT) and the presence of carotid plaque were used as markers of atherosclerosis. C-reactive protein (CRP) and serum interleukin-6 (IL-6) were evaluated as markers of systemic inflammation. Baseline plasma levels of albumin, homocysteine, lipoprotein (a) [Lp(a)] and other lipid parameters were measured. Body mass index and residual renal function (RRF) were calculated. Patients were classified with the Davies co-morbidity score. Results. The dialysate–plasma creatinine ratio (D/P creatinine) was 0.75±0.10; 26% were fast transporters (D/P ≥0.85). In comparison with other transport categories, these had similar age, body mass index and RRF, and did not present a higher co-morbidity score than non-fast transporters. IMT did not significantly differ between groups. By multiple regression analysis, baseline peritoneal small solute transport was not related to systemic inflammation biomarkers. Fast transporters did not present higher levels of CRP or serum IL-6. Plasma levels of lipids, Lp(a), calcium × phosphorus product and albumin also did not differ between groups. Similar results were obtained when patients were grouped according to mass transfer area coefficient for creatinine. Patients with more than two co-morbidities had lower levels of plasma albumin (3.6±0.58 vs 3.9±0.9 g/dl, P = 0.054), significantly higher median levels of serum IL-6 (19.3 vs 9.2 pg/ml, P = 0.003) and wider IMT (0.90±0.36 vs 0.65±0.28 mm, P = 0.017). Multivariate analysis confirmed that baseline peritoneal transport was not a significant determinant of patient survival ( P = 0.848), while the co-morbidity score remained significant (hazard ratio = 3.48, 95% confidence interval = 1.29–9.38, P = 0.014). Conclusion. Initial fast transport was not associated with systemic inflammation and atherosclerosis. In a population with preserved RRF and absence of baseline serious co-morbidity, it was not predictive of worse prognosis. Other determinants of early peritoneal fast transport deserve investigation.

2 September 2013 in Biofouling
Verified
Journal Article
Open access
MMMargarida Martins
Margarida Martins
ARAnabela Rodrigues
Anabela Rodrigues
JPJorge M. Pedrosa
Jorge M. Pedrosa
MCMaria J. Carvalho
Maria J. Carvalho
ACAntónio Cabrita
António Cabrita
RORosário Oliveira
Rosário Oliveira
Biofilms are commonly associated with an increased risk of patient infection. In peritoneal dialysis (PD), catheter associated infection, especially peritonitis, remains a clinically relevant problem. Although the presence of a biofilm is recognized in relapsing, repeat, and catheter-related peritonitis, it remains poorly characterized. In this review, an update on the role of biofilms in PD infections is presented. The emerging concept that host cells and tissue associated biofilms, in addition to the biofilms on the catheters themselves, contribute to the recalcitrance of infections is discussed. Furthermore, the evidence of biofilms on PD catheters, their developmental stages, and the possible influence of the PD environment are reviewed. The focus is given to ex vivo and in vitro studies that contribute to the elucidation of the interplay between host, microbial, and dialysis factors. The key issues that are still to be answered and the challenges to clinical practice are discussed.